![Catherine A. Brady](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Catherine A. Brady
Directeur des opérations chez Celentyx Ltd.
Provenance du réseau au premier degré de Catherine A. Brady
Entité | Type d'entité | Industrie | |
---|---|---|---|
Celentyx Ltd.
![]() Celentyx Ltd. BiotechnologyHealth Technology Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom.
4
| Holding Company | Biotechnology | 4 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Catherine A. Brady via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
University of Birmingham | College/University | Corporate Officer/Principal Corporate Officer/Principal Undergraduate Degree | |
The International Union of Basic & Clinical Pharmacology | Corporate Officer/Principal | ||
The Royal College of Physicians | College/University | Corporate Officer/Principal | |
Spark Therapeutics Ireland Ltd.
![]() Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member | |
CLINIGEN GROUP PLC | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
Glaxo Group Research Ltd. | Corporate Officer/Principal | ||
Zeneca Pharmaceuticals
![]() Zeneca Pharmaceuticals Pharmaceuticals: MajorHealth Technology Zeneca Pharmaceuticals manufactures medicines. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Alan Boyd Consultants Ltd. | Chief Executive Officer | ||
Linear Diagnostics Ltd.
![]() Linear Diagnostics Ltd. Medical SpecialtiesHealth Technology Linear Diagnostics Ltd. operates as a diagnostics company based on a novel technology that allows wide range of molecular diagnostics tests to be carried out using a simple optical system. It specializes in molecular diagnostics, novel technology and optical detection. The company was founded by Matt Hicks in 2011 and is headquartered in Birmingham, the United Kingdom. | Medical Specialties | Director/Board Member | |
AstraZeneca Canada, Inc.
![]() AstraZeneca Canada, Inc. Pharmaceuticals: MajorHealth Technology AstraZeneca Canada, Inc. develops and manufactures pharmaceutical drug preparations. Its therapeutic areas include cardiovascular and metabolic disease, oncology, and respiratory, inflammation and autoimmunity. The firm also active in the infection, neuroscience and gastrointestinal disease areas. The company was founded in 1999 and is headquartered in Mississauga, Canada. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Transine Therapeutics Ltd.
![]() Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | Pharmaceuticals: Major | Director/Board Member |
Statistiques
Internationale
Royaume-Uni | 9 |
Etats-Unis | 3 |
Irlande | 2 |
Canada | 2 |
Sectorielle
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 3 |
Opérationnelle
Director/Board Member | 7 |
Chief Tech/Sci/R&D Officer | 6 |
Corporate Officer/Principal | 5 |
Founder | 3 |
Chief Executive Officer | 2 |
Relations les plus connectées
Insiders | |
---|---|
Alan Keith Boyd | 12 |
Nicholas Mark Barnes | 3 |
John Gordon | 2 |
John Curnow | 1 |
- Bourse
- Insiders
- Catherine A. Brady
- Connexions Sociétés